Sequential is excited to announce the launch of the industry’s first-ever Targeted Skin Condition Panels through the lens of the Microbiome, designed to address major skin concerns such as acne, rosacea, atopic dermatitis, malodor, and sun/UV exposure. These pioneering panels offer a targeted approach to skin research by focusing on the underlying microbial significance of these conditions. Sequential utilises a proprietary qPCR approach for these targeted panels with their in-house Smart ProbesTM, ensuring that results include species and subspecies level analysis as well as absolute quantification.
Contrary to more traditional methods of studying the microbiome, Sequential’s panels offer a uniquely targeted approach, allowing clients to focus their research on specific areas of interest. Sequential’s panels are the result of years of dedicated research by our team of scientists, who have worked extensively to decode the microbial factors that contribute to skin health and conditions. These panels provide researchers with an innovative, data-driven solution to investigate the microbial roots of various skin conditions, unlocking new possibilities for treatment and product development.
Supported by a robust database of over 25,000 microbial samples and countless scientific studies, Sequential’s offering empowers clients with an unprecedented level of precision in their research. The Microbiome Target Panels will be available to clients starting on 16th of October 2024.
“We are proud to bring these groundbreaking tools to the industry. Our panels are designed to revolutionise how skin concerns are studied and addressed, opening new doors for targeted, microbiome-driven solutions.”
said Dr. Albert Dashi, CSO of Sequential.
“Characterising the microbiome with real quantification, at subspecies level, is leading to a refined approach for understanding what and how these microbes are functioning in the human body,”
added Dr. Oliver Worsley, CEO of Sequential.
For more information about Sequential’s Microbiome Targeted Panels, please visit: www.sequential.bio.